CO7131357A2 - Compuestos de n-ariltriazol como antagonistas de lpar - Google Patents
Compuestos de n-ariltriazol como antagonistas de lparInfo
- Publication number
- CO7131357A2 CO7131357A2 CO14255124A CO14255124A CO7131357A2 CO 7131357 A2 CO7131357 A2 CO 7131357A2 CO 14255124 A CO14255124 A CO 14255124A CO 14255124 A CO14255124 A CO 14255124A CO 7131357 A2 CO7131357 A2 CO 7131357A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- aryltriazole
- lpar antagonists
- lpar
- antagonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661953P | 2012-06-20 | 2012-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7131357A2 true CO7131357A2 (es) | 2014-12-01 |
Family
ID=48628669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14255124A CO7131357A2 (es) | 2012-06-20 | 2014-11-20 | Compuestos de n-ariltriazol como antagonistas de lpar |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150133512A1 (enExample) |
| EP (1) | EP2864301A1 (enExample) |
| JP (1) | JP2015520203A (enExample) |
| KR (1) | KR20150011389A (enExample) |
| CN (1) | CN104395299A (enExample) |
| AU (1) | AU2013279513A1 (enExample) |
| BR (1) | BR112014030674A2 (enExample) |
| CA (1) | CA2869564A1 (enExample) |
| CL (1) | CL2014003241A1 (enExample) |
| CO (1) | CO7131357A2 (enExample) |
| EA (1) | EA201492281A1 (enExample) |
| HK (1) | HK1206339A1 (enExample) |
| IL (1) | IL236087A0 (enExample) |
| IN (1) | IN2014DN09352A (enExample) |
| MA (1) | MA37762B1 (enExample) |
| MX (1) | MX2014014711A (enExample) |
| PE (1) | PE20142305A1 (enExample) |
| PH (1) | PH12014502363A1 (enExample) |
| SG (1) | SG11201407228PA (enExample) |
| UA (1) | UA110310C2 (enExample) |
| WO (1) | WO2013189865A1 (enExample) |
| ZA (1) | ZA201408167B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| AU2015281021B9 (en) | 2014-06-27 | 2019-03-28 | Ube Corporation | Salt of halogen-substituted heterocyclic compound |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
| CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
| CN112074515B (zh) | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| TW202017918A (zh) | 2017-12-19 | 2020-05-16 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之環己基酸三唑吖 |
| WO2019126103A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| EP3728210B1 (en) | 2017-12-19 | 2026-02-11 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR20200100713A (ko) | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| JP7526096B2 (ja) * | 2017-12-19 | 2024-07-31 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
| KR102698386B1 (ko) | 2017-12-19 | 2024-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산 |
| KR102697358B1 (ko) | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| CN113366000A (zh) | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| PH12013501136A1 (en) * | 2010-12-07 | 2013-07-08 | Amira Pharmaceuticals Inc | Lysophosphatidic acid receptor antagonists and uses thereof |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| EA201492285A1 (ru) * | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) |
-
2013
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/en not_active Withdrawn
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/en not_active Ceased
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Ceased
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 HK HK15106924.1A patent/HK1206339A1/xx unknown
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
- 2013-06-17 CA CA2869564A patent/CA2869564A1/en not_active Abandoned
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201492281A1 (ru) | 2015-04-30 |
| MA37762A1 (fr) | 2017-07-31 |
| BR112014030674A2 (pt) | 2017-06-27 |
| IL236087A0 (en) | 2015-02-01 |
| EP2864301A1 (en) | 2015-04-29 |
| UA110310C2 (uk) | 2015-12-10 |
| PE20142305A1 (es) | 2015-01-16 |
| PH12014502363A1 (en) | 2015-01-12 |
| ZA201408167B (en) | 2015-12-23 |
| US20150133512A1 (en) | 2015-05-14 |
| AU2013279513A1 (en) | 2014-10-16 |
| CL2014003241A1 (es) | 2015-03-20 |
| KR20150011389A (ko) | 2015-01-30 |
| JP2015520203A (ja) | 2015-07-16 |
| WO2013189865A1 (en) | 2013-12-27 |
| SG11201407228PA (en) | 2014-12-30 |
| CN104395299A (zh) | 2015-03-04 |
| MX2014014711A (es) | 2015-03-04 |
| HK1206339A1 (en) | 2016-01-08 |
| CA2869564A1 (en) | 2013-12-27 |
| MA37762B1 (fr) | 2018-04-30 |
| IN2014DN09352A (enExample) | 2015-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| PE20180318A1 (es) | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| CL2014001174A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
| CU20150021A7 (es) | Piridinonas bicíclicas novedosas | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| ECSP14013215A (es) | Compuestos novedosos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
| BR112015003998A2 (pt) | compostos de cianopirazol lpar-substituídos | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX2013011728A (es) | Nuevos compuestos de benzofurano-piperidina. | |
| CU20100210A7 (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| CU20140021A7 (es) | Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2 | |
| CU20100094A7 (es) | Derivados bis-(sulfonilamino) en terapia 066 |